Merck & Co
(MRK-NYSE)
DRUGS - Drug Manufacturers - Major
Stock report updated on 01/20/2012
- MRK is at or near its 52-week high. Studies have found that such stocks have an increased probability of outperforming the market over the next year.
- Volatility is forecast to fall over the next month.
- With RSI > 70, MRK is overbought. Odds slightly favor a short-term price reversal.
- Price broke above prior resistance level - a short-term bullish signal.
| Closing price: |
$39.20 |
| Support price level: |
$36.46 |
| Resistance price level: |
N/A |
| Relative strength index (14-day RSI): |
73.3 |
| Beta: |
0.58 |
52-Week Range
| Low |
High |
Price as % of Range |
| $29.81 |
$39.26 |
99.4% |
Moving Averages
| 200 day |
50 day |
20 day |
10 day |
| $34.67 |
$36.41 |
$38.28 |
$38.69 |
Volatility (annualized std. dev.)
Historical
(5 year) |
Last month |
Current estimate |
Next month forecast |
| 32.3% |
21.8% |
15.8% |
20.4% |
Value at Risk
There is an estimated 5% probability that the stock price of Merck & Co will fall by more than:
- 4.3% in the next week.
- 11.6% in the next month.
- 42.1% in the next year.
Company News for Merck & Co
Google Finance |
MSN Money |
Reuters
Reports for Other Stocks
